- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
ThromboGenics to launch ocriplasmin in United States
ThromboGenics NV has confirmed a date of Jan. 14 for the U.S. launch of ocriplasmin intravitreal injection (Jetrea).
Leuven, Belgium-ThromboGenics NV has confirmed a date of Jan. 14 for the U.S. launch of ocriplasmin intravitreal injection (Jetrea).
The product is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA). The U.S. price for a single-use glass vial is set at $3,950.
The product represents a paradigm shift and for the first time offers a pharmacological treatment option to patients suffering with symptomatic VMA. The FDA approved Jetrea in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA.
ThromboGenics will be making a presentation concerning the launch on Wednesday, Jan. 9 during the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.
